“Turbocharged” Hair Regrowth: Experimental Extended-Release Minoxidil Pill Shows Unprecedented Results
For the estimated 50 million American men experiencing pattern hair loss, the current treatment options often feel like a compromise. However, a newly developed, “turbocharged” version of a popular hair-growth drug is demonstrating dramatic results in clinical trials, potentially paving the way for the first FDA-approved oral pill for hair loss in nearly three decades.
Developed by Connecticut-based pharmaceutical company Veradermics, the experimental drug—named VDPHL01—is an extended-release oral formulation of minoxidil. According to the company, this new pill delivers twice the amount of the active drug over a 12-hour period compared to standard versions.
The Breakthrough: Fixing a “Borrowed” Cardiology Drug
Currently, Americans spend an estimated $3.5 billion annually on hair loss treatments. For decades, oral minoxidil has been prescribed off-label for hair loss. The drug works by relaxing blood vessels and boosting blood flow, which in turn delivers more oxygen and nutrients to hair follicles to trigger regrowth.
However, as Dr. Michael Gold, a dermatologist and clinical investigator for the trial, points out, the current approach has been deeply flawed:
“Dermatology has been treating hair loss with a drug borrowed from cardiology, in a formulation never intended for our patients, at doses we arrived at informally. VDPHL01 is the first oral minoxidil formulation developed specifically for pattern hair loss.”
While standard minoxidil is typically prescribed informally in doses between 1mg and 5mg, the new extended-release VDPHL01 pill contains 8.5 mg of the active ingredient, designed for safe, steady absorption.
The Trial Results: By the Numbers
In a Phase 2/3 clinical trial involving more than 500 men, the results of the experimental drug were striking. Researchers found that patients taking VDPHL01 once or twice daily saw significant improvements within just two months.
After a six-month period, the data showed a massive divide between the treatment group and the placebo group:
| Trial Metric (After 6 Months) | VDPHL01 (Experimental Drug) | Placebo Group |
| New Hairs per Square Centimeter | Gained 30 to 33 new hairs | Gained 7 new hairs |
| Visible Overall Improvement | 79% to 86% of patients | 35% of patients |
The above was among the best results from the experimental form of minoxidil that was tested in the trial
Understanding the Side Effects and Safety Profile
Historically, doctors have hesitated to prescribe high doses of oral minoxidil due to the risk of cardiovascular side effects, such as irregular heartbeats or high blood pressure. A 2022 meta-analysis warned that every 1mg increase in standard minoxidil elevated the risk of cardiovascular issues by 5%.
However, Veradermics reports that their 8.5mg extended-release formula was generally well-tolerated, with no treatment-related serious cardiac events recorded.
-
Overall Adverse Events: Roughly 40% of patients in both the active and placebo groups reported at least one adverse event.
-
Swelling (Edema): About 5% of patients on the experimental drug experienced peripheral edema (swelling in the legs, ankles, or hands), compared to a 7% warning label rate on current standard prescriptions.
-
Unwanted Hair Growth (Hypertrichosis): About 5% experienced hair growth on other parts of the body. In stark contrast, standard minoxidil triggers this side effect in roughly 80% of patients within the first few months.
-
Dropout Rate: Only 4 out of the 346 patients taking VDPHL01 discontinued use due to side effects.
What Happens Next?
While the trial results are incredibly promising for the 95% of men who will experience hair loss in their lifetimes, VDPHL01 is not available at the pharmacy just yet. The drug must still undergo further Phase 3 trials and secure official FDA approval before it hits the market.
“If approved, VDPHL01 has the potential to transform how physicians and patients approach pattern hair loss,” says Dr. Maryanne Senna, a dermatologist on Veradermics’ scientific advisory board. For millions of men, that transformation can’t come soon enough.
